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Abstract
In order to laboratory conﬁrm the ﬁrst suspected West Nile fever
case in 2013 in northern Greece, a combination of serological
molecular and culture methods were applied. It was shown that
the causative West Nile virus strain belonged to lineage 2, and
possessed the amino acid substitution H249P in the NS3 protein,
as in previous years. The signiﬁcance of this speciﬁc strain in
Europe remains to be elucidated.
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Introduction
West Nile virus (WNV) is a mosquito-borne ﬂavivirus (genus
Flavivirus, family Bunyaviridae) causing an asymptomatic or
mild infection (West Nile fever) in humans, while in less than
1% of infections there are symptoms from the nervous system
(West Nile neuroinvasive disease). Most WNV strains cluster
into two major genetic lineages 1 and 2. Lineage 1, is
responsible for sporadic cases and outbreaks in Africa, Asia,
Australia and the Americas. Lineage 2, initially restricted to
sub-Saharan Africa and Madagascar, emerged in 2004 in
Europe, and caused a large outbreak of WNV infections in
2010 in Greece (WNV strain Nea Santa-Greece-2010) [1,2].
Genetic characterization of the strain showed that its closest
genetic relationship was to the lineage 2 strain that had
emerged in Hungary in 2004, and it was suggested that the
increased virulence might be associated with the amino acid
substitution H249P in the NS3 protein [3]. Since then, Greece
has experienced outbreaks for three consecutive years (2010–
2012) with 381 cases of West Nile neuroinvasive disease [4].
The geographical range of WNV in Europe is expanding and
the virus is causing increasing numbers of epidemics/outbreaks
associated with human morbidity and mortality [5]. Here, we
report the laboratory-conﬁrmed diagnosis of the ﬁrst West
Nile fever case observed in 2013 in northern Greece.
In mid-July 2013 a 73-year-old male resident of Thessaloniki,
northern Greece, with a history of diabetes mellitus, coronary
disease and dementia, was admitted to Agios Demetrios
General Hospital in Thessaloniki, because of 4-day high fever
(39.7°C), chills, severe headache, cough, nausea and vomiting.
Upon admission the patient was disorientated. His blood
pressure was 140/80 mmHg with a heart rate of 70 beats per
minute. Main laboratory ﬁndings were: white blood cell count
14 000 cells/mL (neutrophils 72.6%, lymphocytes 17%, mono-
cytes 9.9%); haematocrit 38.7%; platelets 108 000/mL; eryth-
rocyte sedimentation rate 66 mm/h; C-reactive protein
3.2 mg/L (normal <3 mg/L); hyponatraemia 126 mmol/L (nor-
mal range 135–145 mmol/L); alanine transaminase 54 U/L;
aspartate transaminase 65 U/L (normal range for both trans-
aminases up to 35 U/L); and lactate dehydrogenase 409 U/L
(normal range 140–280 U/L). No lumbar puncture was
performed. The physical and neurological examination did
not show any abnormalities, apart from reduced visual acuity
due to cataract. Results of the chest radiography and
electrocardiogram were normal, while a computed tomogra-
phy scan of the brain showed generalized atrophy. The patient
was started on antimicrobial drug therapy (intravenous
ceftriaxone and azithromycin) for potential bacterial infection.
Blood and urine cultures were negative. He continued to be
febrile up to day 5 of hospitalization.
On the basis of the patient’s clinical symptoms, and the
several cases of WNV infection in northern Greece during the
last 3 years, WNV infection was suspected. A serum sample
from the patient was sent to the Hellenic Reference Centre
for Arboviruses in Aristotle University of Thessaloniki for the
detection of WNV IgM and IgG antibodies. Using commercial
ELISA kits (WNV IgM capture DxSelectTM and WNV IgG
DxSelect; Focus Diagnostics Inc., Cypress, CA, USA), WNV
IgM antibodies were detected, but IgG antibodies were not
detectable. A second serum sample, together with blood and
urine samples, was taken on day 7 after admission (11th day of
illness). High levels of both IgM and IgG antibodies were
detected in the second sample, which was also tested by
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plaque reduction neutralization test and >90% reduction was
observed (PRNT90).
A real-time RT-PCR [6] was applied on genetic material
extracted from the plasma and urine samples of the patient
(taken on the 11th day of illness), which gave negative results
for the plasma sample but positive for the urine sample, with
Ct value of 26.95. WNV RNA detection in urine has been
proposed as a diagnostic method for WNV infection, because
it is detectable at a higher viral load and for longer time in
urine than in plasma and it has been successfully followed as
routine testing for the diagnosis and follow-up of patients with
WNV infection [7,8].
Upon receipt of the urine sample, 1 mL of 1 : 10 urine
dilution was inoculated in Vero E6 cells, and ﬂasks were
observed daily for the presence of cytopathic effects, which
were seen on day 3 after inoculation. Real-time PCR on the
genetic material extracted from the cell supernatant gave
positive results with Ct 19.60. We continued the propagation
of the virus up to the sixth passage. Spot-slides prepared with
the infected cells gave strong immunoﬂuorescence with a
known WNV IgG-positive serum. Hence, although the patient
had already high titres of IgG and IgM antibodies, he continued
to have viruria. To check whether the WNV strain of 2013
(North Greece-2013) possesses the H249P substitution in the
NS3 protein, we applied an RT-nested PCR, with previously
designed primers speciﬁc for this genome region [9]. Nucle-
otide sequencing analysis showed 100% identity with the Nea
Santa-Greece-2010 strain, suggesting that the WNV strain of
2013 possess the H249P substitution (GenBank accession
number KF537659).
The condition of the patient improved on day 7 of
hospitalization, however, he was still complaining of headache.
The haematological and biochemical parameters returned to
normal and the patient was discharged on day 11 of
hospitalization without any sequelae.
In the present study we report all the laboratory methods
applied at a reference centre to three types of samples taken
from the ﬁrst suspected WNV case in northern Greece in
2013 in order ﬁrst to conﬁrm the diagnosis and then to gain an
insight into the WNV strain that is causing clinical cases at the
start of the WNV season. Although a lot of laboratory effort is
needed to complete the procedure in the required time, it
provides useful data for the WNV epidemiology in the
country. For cases that might follow, serology and real-time
RT-PCR are sufﬁcient for WNV diagnostics, while PRNT90
could be applied on batches of samples once or twice per
month as a conﬁrmatory test of the probable cases.
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